{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:00:55Z","timestamp":1784293255917,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32100955"],"award-info":[{"award-number":["32100955"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81900209"],"award-info":[{"award-number":["81900209"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81872322"],"award-info":[{"award-number":["81872322"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of Zhejiang Province","award":["LZ22H160009"],"award-info":[{"award-number":["LZ22H160009"]}]},{"name":"Zhejiang Key Research and Development Project","award":["2020C03014"],"award-info":[{"award-number":["2020C03014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple myeloma (MM) is the second most common hematologic malignancy with almost all patients eventually having relapse or refractory MM (RRMM), thus novel drugs or combination therapies are needed for improved prognosis. Chidamide and venetoclax, which target histone deacetylase and BCL2, respectively, are two promising agents for the treatment of RRMM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Herein, we found that chidamide and venetoclax synergistically exert an anti-myeloma effect in vitro in human myeloma cell lines (HMCLs) with a combination index (CI)\u2009&lt;\u20091. Moreover, the synergistic anti-myeloma effect of these two drugs was demonstrated in primary MM cells and MM xenograft mice. Mechanistically, co-exposure to chidamide and venetoclax led to cell cycle arrest at G0\/G1 and a sharp increase in DNA double-strand breaks. In addition, the combination of chidamide and venetoclax resulted in BCL-X<jats:sub>L<\/jats:sub> downregulation and BIM upregulation, and the latter protein was proved to play a critical role in sensitizing HMCLs to co-treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, these results proved the high therapeutic potential of venetoclax and chidamide combination in curing MM, representing a potent and alternative salvage therapy for the treatment of RRMM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13148-022-01306-7","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T12:03:12Z","timestamp":1657195392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression"],"prefix":"10.1186","volume":"14","author":[{"given":"Liqin","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enfan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"issue":"7","key":"1306_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. New Engl J Med. 2020;383(7):617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"New Engl J Med"},{"issue":"12","key":"1306_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, et al. Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia. New Engl J Med. 2018;378(12):1107\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1713976.","journal-title":"New Engl J Med"},{"issue":"24","key":"1306_CR3","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137\u201345. https:\/\/doi.org\/10.1182\/blood.2020004856.","journal-title":"Blood"},{"issue":"23","key":"1306_CR4","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. New Engl J Med. 2019;380(23):2225\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1815281.","journal-title":"New Engl J Med"},{"issue":"7","key":"1306_CR5","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood.2020008727","volume":"137","author":"S Le Gouill","year":"2021","unstructured":"Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial. Blood. 2021;137(7):877\u201387. https:\/\/doi.org\/10.1182\/blood.2020008727.","journal-title":"Blood"},{"issue":"6","key":"1306_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.25796","volume":"95","author":"S Zhao","year":"2020","unstructured":"Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020;95(6):623\u20139. https:\/\/doi.org\/10.1002\/ajh.25796.","journal-title":"Am J Hematol"},{"issue":"14","key":"1306_CR7","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1182\/blood-2010-11-317438","volume":"118","author":"L Bodet","year":"2011","unstructured":"Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Ma\u00efga S, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood. 2011;118(14):3901\u201310. https:\/\/doi.org\/10.1182\/blood-2010-11-317438.","journal-title":"Blood"},{"issue":"22","key":"1306_CR8","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401\u20139. https:\/\/doi.org\/10.1182\/blood-2017-06-788786.","journal-title":"Blood"},{"issue":"12","key":"1306_CR9","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/s1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(20)30525-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1306_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/leu.2013.216","volume":"28","author":"C Touzeau","year":"2014","unstructured":"Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210\u20132. https:\/\/doi.org\/10.1038\/leu.2013.216.","journal-title":"Leukemia"},{"issue":"5","key":"1306_CR11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1535-7163.Mct-15-0730","volume":"15","author":"EA Punnoose","year":"2016","unstructured":"Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15(5):1132\u201344. https:\/\/doi.org\/10.1158\/1535-7163.Mct-15-0730.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1306_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69. https:\/\/doi.org\/10.1186\/s13045-017-0439-6.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1306_CR13","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(8):1766\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdv237.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"8","key":"1306_CR14","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3324\/haematol.2017.181172","volume":"103","author":"J He","year":"2018","unstructured":"He J, Chen Q, Gu H, Chen J, Zhang E, Guo X, et al. Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease. Haematologica. 2018;103(8):1369\u201379. https:\/\/doi.org\/10.3324\/haematol.2017.181172.","journal-title":"Haematologica"},{"key":"1306_CR15","doi-asserted-by":"publisher","first-page":"569651","DOI":"10.3389\/fphar.2020.569651","volume":"11","author":"L Lin","year":"2020","unstructured":"Lin L, Que Y, Lu P, Li H, Xiao M, Zhu X, et al. Chidamide inhibits acute myeloid leukemia cell proliferation by lncRNA VPS9D1-AS1 downregulation via MEK\/ERK signaling pathway. Front Pharmacol. 2020;11:569651. https:\/\/doi.org\/10.3389\/fphar.2020.569651.","journal-title":"Front Pharmacol"},{"key":"1306_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111794","author":"E San Jos\u00e9-En\u00e9riz","year":"2019","unstructured":"San Jos\u00e9-En\u00e9riz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid leukemia. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11111794.","journal-title":"Cancers"},{"issue":"9","key":"1306_CR17","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41375-018-0223-9","volume":"32","author":"C Touzeau","year":"2018","unstructured":"Touzeau C, Maciag P, Amiot M, Moreau P. Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia. 2018;32(9):1899\u2013907. https:\/\/doi.org\/10.1038\/s41375-018-0223-9.","journal-title":"Leukemia"},{"issue":"4","key":"1306_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/leu.2008.1","volume":"22","author":"S Inoue","year":"2008","unstructured":"Inoue S, Walewska R, Dyer MJ, Cohen GM. Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia. 2008;22(4):819\u201325. https:\/\/doi.org\/10.1038\/leu.2008.1.","journal-title":"Leukemia"},{"issue":"3","key":"1306_CR19","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1158\/0008-5472.Can-15-1751","volume":"76","author":"CM Adams","year":"2016","unstructured":"Adams CM, Hiebert SW, Eischen CM. Myc induces miRNA-mediated apoptosis in response to HDAC inhibition in hematologic malignancies. Cancer Res. 2016;76(3):736\u201348. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-1751.","journal-title":"Cancer Res"},{"issue":"9","key":"1306_CR20","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2014.81","volume":"28","author":"SL Locatelli","year":"2014","unstructured":"Locatelli SL, Cleris L, Stirparo GG, Tartari S, Saba E, Pierdominici M, et al. BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. Leukemia. 2014;28(9):1861\u201371. https:\/\/doi.org\/10.1038\/leu.2014.81.","journal-title":"Leukemia"},{"issue":"9","key":"1306_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","volume":"58","author":"P Bose","year":"2017","unstructured":"Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58(9):1\u201317. https:\/\/doi.org\/10.1080\/10428194.2017.1283032.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"1306_CR22","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","volume":"11","author":"I Kapoor","year":"2020","unstructured":"Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis. 2020;11(11):941\u2013941. https:\/\/doi.org\/10.1038\/s41419-020-03144-y.","journal-title":"Cell Death Dis"},{"issue":"4","key":"1306_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.biopha.2014.03.011","volume":"68","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Pan DS, Shan S, Zhu JZ, Zhang K, Yue XP, et al. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in non-small-cell lung cancer cells. Biomed Pharmacother. 2014;68(4):483\u201391. https:\/\/doi.org\/10.1016\/j.biopha.2014.03.011.","journal-title":"Biomed Pharmacother"},{"key":"1306_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13148-017-0377-8","volume":"9","author":"Y Li","year":"2017","unstructured":"Li Y, Wang Y, Zhou Y, Li J, Chen K, Zhang L, et al. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells. Clin Epigenetics. 2017;9:83. https:\/\/doi.org\/10.1186\/s13148-017-0377-8.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"1306_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13148-019-0723-0","volume":"11","author":"J Ye","year":"2019","unstructured":"Ye J, Zha J, Shi Y, Li Y, Yuan D, Chen Q, et al. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair. Clin Epigenetics. 2019;11(1):137. https:\/\/doi.org\/10.1186\/s13148-019-0723-0.","journal-title":"Clin Epigenetics"},{"issue":"7066","key":"1306_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nature04148","volume":"438","author":"T Tsukuda","year":"2005","unstructured":"Tsukuda T, Fleming AB, Nickoloff JA, Osley MA. Chromatin remodelling at a DNA double-strand break site in Saccharomyces cerevisiae. Nature. 2005;438(7066):379\u201383. https:\/\/doi.org\/10.1038\/nature04148.","journal-title":"Nature"},{"issue":"5","key":"1306_CR27","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.molcel.2007.11.015","volume":"28","author":"JW Harper","year":"2007","unstructured":"Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007;28(5):739\u201345. https:\/\/doi.org\/10.1016\/j.molcel.2007.11.015.","journal-title":"Mol Cell"},{"issue":"1","key":"1306_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/blood.v100.1.194","volume":"100","author":"S Derenne","year":"2002","unstructured":"Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002;100(1):194\u20139. https:\/\/doi.org\/10.1182\/blood.v100.1.194.","journal-title":"Blood"},{"issue":"7","key":"1306_CR29","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","volume":"19","author":"S Wuill\u00e8me-Toumi","year":"2005","unstructured":"Wuill\u00e8me-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005;19(7):1248\u201352. https:\/\/doi.org\/10.1038\/sj.leu.2403784.","journal-title":"Leukemia"},{"issue":"5","key":"1306_CR30","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","volume":"118","author":"AA Morales","year":"2011","unstructured":"Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, et al. Distribution of bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1-expressing myeloma cells. Blood. 2011;118(5):1329\u201339. https:\/\/doi.org\/10.1182\/blood-2011-01-327197.","journal-title":"Blood"},{"issue":"20","key":"1306_CR31","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1007\/s00018-014-1656-6","volume":"71","author":"J Zhang","year":"2014","unstructured":"Zhang J, Zhong Q. Histone deacetylase inhibitors and cell death. Cell Mol Life Sci CMLS. 2014;71(20):3885\u2013901. https:\/\/doi.org\/10.1007\/s00018-014-1656-6.","journal-title":"Cell Mol Life Sci CMLS"},{"key":"1306_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55020030","author":"U Natarajan","year":"2019","unstructured":"Natarajan U, Venkatesan T, Radhakrishnan V, Samuel S, Rasappan P, Rathinavelu A. Cell cycle arrest and cytotoxic effects of SAHA and RG7388 mediated through p21(WAF1\/CIP1) and p27(KIP1) in cancer cells. Medicina (Kaunas, Lithuania). 2019. https:\/\/doi.org\/10.3390\/medicina55020030.","journal-title":"Medicina (Kaunas, Lithuania)"},{"issue":"8","key":"1306_CR33","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3324\/haematol.2017.181172","volume":"103","author":"H Jingsong","year":"2018","unstructured":"Jingsong H, Qingxiao C, Huiyao G, Jing C, Enfan Z, Xing G, et al. Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease. Haematologica. 2018;103(8):1369\u201379. https:\/\/doi.org\/10.3324\/haematol.2017.181172.","journal-title":"Haematologica"},{"issue":"1","key":"1306_CR34","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1038\/s41467-021-23612-z","volume":"12","author":"LR Pack","year":"2021","unstructured":"Pack LR, Daigh LH, Chung M, Meyer T. Clinical CDK4\/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2. Nat Commun. 2021;12(1):3356. https:\/\/doi.org\/10.1038\/s41467-021-23612-z.","journal-title":"Nat Commun"},{"issue":"3","key":"1306_CR35","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/jcp.24819","volume":"230","author":"A Roy","year":"2015","unstructured":"Roy A, Banerjee S. p27 and leukemia: cell cycle and beyond. J Cell Physiol. 2015;230(3):504\u20139. https:\/\/doi.org\/10.1002\/jcp.24819.","journal-title":"J Cell Physiol"},{"key":"1306_CR36","doi-asserted-by":"publisher","first-page":"13357","DOI":"10.2147\/ott.S281519","volume":"13","author":"A Alhoshani","year":"2020","unstructured":"Alhoshani A, Alatawi FO, Al-Anazi FE, Attafi IM, Zeidan A, Agouni A, et al. BCL-2 inhibitor venetoclax induces autophagy-associated cell death, cell cycle arrest, and apoptosis in human breast cancer cells. OncoTargets Ther. 2020;13:13357\u201370. https:\/\/doi.org\/10.2147\/ott.S281519.","journal-title":"OncoTargets Ther"},{"issue":"3","key":"1306_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/s1534-5807(04)00067-x","volume":"6","author":"JA Coffman","year":"2004","unstructured":"Coffman JA. Cell cycle development. Dev Cell. 2004;6(3):321\u20137. https:\/\/doi.org\/10.1016\/s1534-5807(04)00067-x.","journal-title":"Dev Cell"},{"issue":"1","key":"1306_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23(1):74\u201388. https:\/\/doi.org\/10.1038\/s41580-021-00404-3.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"21","key":"1306_CR39","doi-asserted-by":"publisher","first-page":"10017","DOI":"10.1093\/nar\/gkw922","volume":"44","author":"WP Roos","year":"2016","unstructured":"Roos WP, Krumm A. The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair. Nucl Acids Res. 2016;44(21):10017\u201330. https:\/\/doi.org\/10.1093\/nar\/gkw922.","journal-title":"Nucl Acids Res"},{"key":"1306_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/b978-0-12-394387-3.00003-3","volume":"116","author":"C Robert","year":"2012","unstructured":"Robert C, Rassool FV. HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res. 2012;116:87\u2013129. https:\/\/doi.org\/10.1016\/b978-0-12-394387-3.00003-3.","journal-title":"Adv Cancer Res"},{"key":"1306_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618908","author":"D Yuan","year":"2021","unstructured":"Yuan D, Li G, Yu L, Jiang Y, Shi Y, Chen Q, et al. CS2164 and venetoclax show synergistic antitumoral activities in high grade B-Cell lymphomas with MYC and BCL2 rearrangements. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.618908.","journal-title":"Front Oncol"},{"issue":"5828","key":"1306_CR42","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1140321","volume":"316","author":"S Matsuoka","year":"2007","unstructured":"Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science (New York, NY). 2007;316(5828):1160\u20136. https:\/\/doi.org\/10.1126\/science.1140321.","journal-title":"Science (New York, N.Y.)"},{"key":"1306_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/b978-0-12-380888-2.00003-0","volume":"108","author":"J Smith","year":"2010","unstructured":"Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010;108:73\u2013112. https:\/\/doi.org\/10.1016\/b978-0-12-380888-2.00003-0.","journal-title":"Adv Cancer Res"},{"issue":"2","key":"1306_CR44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nsmb.2211","volume":"19","author":"L Feng","year":"2012","unstructured":"Feng L, Chen J. The E3 ligase RNF8 regulates KU80 removal and NHEJ repair. Nat Struct Mol Biol. 2012;19(2):201\u20136. https:\/\/doi.org\/10.1038\/nsmb.2211.","journal-title":"Nat Struct Mol Biol"},{"issue":"6009","key":"1306_CR45","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1126\/science.1190217","volume":"330","author":"D Ren","year":"2010","unstructured":"Ren D, Tu HC, Kim H, Wang GX, Bean GR, Takeuchi O, et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science (New York, NY). 2010;330(6009):1390\u20133. https:\/\/doi.org\/10.1126\/science.1190217.","journal-title":"Science (New York, N.Y.)"},{"issue":"268","key":"1306_CR46","doi-asserted-by":"publisher","first-page":"ra20","DOI":"10.1126\/scisignal.2003483","volume":"6","author":"GR Bean","year":"2013","unstructured":"Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM, et al. PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci Signal. 2013;6(268):ra20. https:\/\/doi.org\/10.1126\/scisignal.2003483.","journal-title":"Sci Signal"},{"issue":"1","key":"1306_CR47","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","volume":"6","author":"R Zhu","year":"2021","unstructured":"Zhu R, Li L, Nguyen B, Seo J, Wu M, Seale T, et al. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation. Signal Transduct Target Ther. 2021;6(1):186. https:\/\/doi.org\/10.1038\/s41392-021-00578-4.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1306_CR48","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","volume":"332","author":"V Del Gaizo Moore","year":"2013","unstructured":"Del Gaizo Moore V, Letai A. BH3 profiling\u2013measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013;332(2):202\u20135. https:\/\/doi.org\/10.1016\/j.canlet.2011.12.021.","journal-title":"Cancer Lett"},{"issue":"12","key":"1306_CR49","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/17474086.2018.1548931","volume":"11","author":"I Vaxman","year":"2018","unstructured":"Vaxman I, Sidiqi MH, Gertz M. Venetoclax for the treatment of multiple myeloma. Expert Rev Hematol. 2018;11(12):915\u201320. https:\/\/doi.org\/10.1080\/17474086.2018.1548931.","journal-title":"Expert Rev Hematol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-022-01306-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-022-01306-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-022-01306-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T12:03:36Z","timestamp":1657195416000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-022-01306-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1186\/s13148-022-01306-7","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"16 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Animal Care and Use Committee of Zhejiang University school of medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}